Evidence map›Paper›PMID 26990989›Full record

ArticleMolecular cell2016

SON and Its Alternatively Spliced Isoforms Control MLL Complex-Mediated H3K4me3 and Transcription of Leukemia-Associated Genes.

Jung-Hyun Kim, Melody C Baddoo, Eun Young Park, Joshua K Stone, Hyeonsoo Park, Thomas W Butler, Gang Huang, Xiaomei Yan, Florencia Pauli-Behn, Richard M Myers and 4 more

Open access · greenAbstract read
In one paragraph

Article in Molecular cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 56 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. SON is an essential mCell stem cell · 2023
    Article
  9. Article
  10. Neurology. Genetics · 2023
    Article
  11. Distinctive Brain Malformations in Zhu-Tokita-Takenouchi-Kim Syndrome.AJNR. American journal of neuroradiology · 2022
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Jung-Hyun KimMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Melody C BaddooTulane Cancer Center, Tulane University, New Orleans, LA 70112, USA.
Eun Young ParkMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Joshua K StoneMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Hyeonsoo ParkDepartment of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Thomas W ButlerMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Gang HuangDivision of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Xiaomei YanDivision of Pathology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA; Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA.
Florencia Pauli-BehnHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Richard M MyersHudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
Ming TanMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA.
Erik K FlemingtonTulane Cancer Center, Tulane University, New Orleans, LA 70112, USA.
Ssang-Taek LimDepartment of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA.
Eun-Young Erin AhnMitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA; Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA. Electronic address: eahn@health.southalabama.edu.
USA Mitchell Cancer Institute · USCincinnati Children's Hospital Medical Center · USHudsonAlpha Institute for Biotechnology · USTulane University · USUniversity of South Alabama · US

Funding

Epstein Barr virus antisense transcriptionR01AI106676 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2014 to 2018
$1.9M
Intercellular communication in Epstein Barr virus reactivationR01AI101046 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI FLEMINGTON, ERIK K · 2012 to 2016
$1.9M
SON-mediated gene expression and leukemiaR01CA190688 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI AHN, ERIN EUN-YOUNG · 2016 to 2021
$1.7M
SON and the MALAT1 locus in chromatin interaction and metastasis gene regulationR21CA185818 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI AHN, ERIN EUN-YOUNG · 2015 to 2016
$362k
NCI NIH HHS R01 CA190688NCI NIH HHS R01CA190688NCI NIH HHS R21 CA185818NCI NIH HHS R21CA185818NIAID NIH HHS R01 AI101046NIAID NIH HHS R01 AI106676
6 · The paper itself

Abstract

Dysregulation of MLL complex-mediated histone methylation plays a pivotal role in gene expression associated with diseases, but little is known about cellular factors modulating MLL complex activity. Here, we report that SON, previously known as an RNA splicing factor, controls MLL complex-mediated transcriptional initiation. SON binds to DNA near transcription start sites, interacts with menin, and inhibits MLL complex assembly, resulting in decreased H3K4me3 and transcriptional repression. Importantly, alternatively spliced short isoforms of SON are markedly upregulated in acute myeloid leukemia. The short isoforms compete with full-length SON for chromatin occupancy but lack the menin-binding ability, thereby antagonizing full-length SON function in transcriptional repression while not impairing full-length SON-mediated RNA splicing. Furthermore, overexpression of a short isoform of SON enhances replating potential of hematopoietic progenitors. Our findings define SON as a fine-tuner of the MLL-menin interaction and reveal short SON overexpression as a marker indicating aberrant transcriptional initiation in leukemia.

Indexed as

Transcription, GeneticAlternative SplicingCell Line, TumorChromatinDNA-Binding ProteinsGene Expression Regulation, LeukemicHistone-Lysine N-MethyltransferaseHumansLeukemia, Myeloid, AcuteMethylationMinor Histocompatibility AntigensMyeloid-Lymphoid Leukemia ProteinProtein BindingProtein IsoformsProto-Oncogene ProteinsChromatinDNA-Binding ProteinsHistone-Lysine N-MethyltransferaseKMT2A protein, humanMEN1 protein, humanMinor Histocompatibility AntigensMyeloid-Lymphoid Leukemia ProteinProtein IsoformsProto-Oncogene ProteinsSON protein, human

Identifiers

PMID26990989
PMCPMC4799497
OpenAlexW2298099976

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.